News

Ocular Therapeutix to Showcase Innovations at Upcoming Meetings

Ocular Therapeutix to Showcase Innovations at Upcoming Meetings

Ocular Therapeutix Showcases Innovations at Industry Meetings

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company dedicated to improving vision through innovative therapies targeting retinal diseases and other eye conditions. With a strong commitment to enhancing patient outcomes, Ocular Therapeutix is set to participate in multiple panels and presentations at various ophthalmology meetings in October 2024, specifically highlighting advancements in retinal therapeutics.

Upcoming Ophthalmology Meetings

During October 2024, Ocular Therapeutix will be actively participating in three significant ophthalmology gatherings. These events include key presentations and panel discussions that will feature the insights of leading experts in the field.

Eyecelerator at AAO 2024

The first event Ocular Therapeutix will attend is the Eyecelerator session at the American Academy of Ophthalmology (AAO) 2024 conference. Scheduled for October 17, the company will present a panel titled "Fueling Progress: The Power of Innovation and Perseverance," featuring Pravin U. Dugel, MD, the Executive Chair, President, and CEO. This panel discussion will take place from 10:00 to 11:00 AM CT.

Company Presentation on Retinal Focus

On the same day, Ocular Therapeutix will deliver a crucial presentation on its transformation into a company focused on retinal therapies. The session, titled "Ocular Therapeutix: Transformation Into A Retina-focused Company," will occur during the Retina Showcase at 1:24 PM CT, where Peter K. Kaiser, MD, Chief Development Officer, will present insights into the company's strategic advancements.

Participation in Innovate RETINA 2024

Following the Eyecelerator session, Ocular Therapeutix will also be represented at Innovate RETINA 2024, where it will take part in another panel discussion titled "The Future of Retinal Therapeutics." This session is planned for the evening of October 17 at 6:30 PM CT, again featuring Dr. Dugel.

American Academy of Ophthalmology Conference

The AAO conference, running from October 18 to 21, will also provide Ocular Therapeutix with an excellent platform to showcase their research. Among the highlights is poster presentation scheduled for the conference on the sustained efficacy of OTX-TKI in the treatment of nAMD, presented by David A. Eichenbaum, MD, FASRS. Ocular Therapeutix encourages those interested to find a full copy of the poster on their official website under the "Investors" section.

About Ocular Therapeutix

Ocular Therapeutix is recognized for its innovative approach to ocular therapies, particularly through its proprietary ELUTYX technology, which is pivotal to its flagship product candidate AXPAXLI (OTX-TKI). This product is currently undergoing Phase 3 clinical trials for wet age-related macular degeneration. Furthermore, the company’s pipeline includes significant products like DEXTENZA, an FDA-approved solution for ocular inflammation, and PAXTRAVA, which addresses glaucoma and ocular hypertension.

Ocular Therapeutix remains committed to enhancing the quality of life for patients through rigorous scientific exploration and product development, utilizing the latest technological advancements in the field.

Contact Information

For media and investor inquiries, Ocular Therapeutix can be contacted via:

Bill Slattery
Vice President, Investor Relations
Email: bslattery@ocutx.com

Frequently Asked Questions

What is Ocular Therapeutix focused on?

Ocular Therapeutix is dedicated to developing innovative therapies for retinal diseases and enhancing overall vision health.

When will Ocular Therapeutix present at the AAO conference?

Ocular Therapeutix will present at the AAO conference from October 18 to 21, with multiple sessions on October 17.

Who are the key presenters for Ocular Therapeutix?

Key presenters include Pravin U. Dugel, MD, and Peter K. Kaiser, MD, showcasing their expertise in retinal therapeutics.

What is AXPAXLI used for?

AXPAXLI is an investigational product intended for the treatment of wet age-related macular degeneration (wet AMD).

Where can one find more information about Ocular Therapeutix's presentations?

More details and copies of presentations are available on the Ocular Therapeutix website under the "Investors" page.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 110

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 36

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 12

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 72

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 97

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 68

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 148

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 118

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 73

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Cooling Garment Enhances Comfort and Safety

Updated Category News Views 195

Innovative Cooling Garment Enhances Comfort and Safety An inventive idea emerges from Pittsburgh, where a passionate creator from Yonkers has designed a unique garment to provide comfort during hot weather. This innovative attire, aptly named the GAIT, offers a cooling effect that surrounds wearers, ensuring they stay safe and comfortable no matter the temperature. The...

Continue Reading
Discovering Next-Gen Oncology Treatments at the ASH Meeting

Updated Category News Views 229

Innovative Presentations from Nurix Therapeutics NURIX Therapeutics, Inc. (NASDAQ: NRIX), a pioneering biopharmaceutical company dedicated to transforming cancer treatment, is set to showcase its significant advancements at a renowned medical meeting. Updated clinical data from the NX-5948-301 Phase 1a/1b trial has been selected for presentation at the 67th American...

Continue Reading
OU Health Partners with Razom to Transform Surgical Training

Updated Category News Views 264

OU Health and Razom Enhance Humanitarian Surgical Training In an inspiring collaboration, OU Health has recently welcomed a significant cohort of Ukrainian surgeons into its humanitarian training program, marking an important milestone in providing essential surgical training for those addressing complex trauma injuries. Expanding the Program The program, which has just...

Continue Reading
Investors Urged to Act: Lead the Charge Against Sarepta

Updated Category News Views 150

Investors May Have A Path Forward Against Sarepta Therapeutics For those who invested in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and have faced significant losses, recent developments present an opportunity to take action. There exists a growing concern regarding the safety implications of one of the company’s leading products, raising questions about transparency and...

Continue Reading
Lindian's Bold Leap into Rare Earths Processing

Updated Category News Views 58

Changing the Game in Rare Earths When Lindian Resources announces a partnership, it's not just window dressing. This time, they've linked arms with Carester SAS for a hefty venture into oxide separation. The scope? An 8,000-tonne REO facility in Kazakhstan, a place already stamped as a geological treasure chest. We're staring at what could potentially be a new dawn for...

Continue Reading